Rice Hall James & Associates LLC Has $6.02 Million Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX)

Rice Hall James & Associates LLC raised its stake in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 47.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 111,133 shares of the company’s stock after acquiring an additional 35,664 shares during the period. Rice Hall James & Associates LLC’s holdings in MoonLake Immunotherapeutics were worth $6,018,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Congress Asset Management Co. raised its holdings in MoonLake Immunotherapeutics by 9.5% in the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company’s stock valued at $3,953,000 after acquiring an additional 6,352 shares in the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of MoonLake Immunotherapeutics by 2.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 79,648 shares of the company’s stock worth $4,313,000 after buying an additional 2,180 shares during the last quarter. Barclays PLC lifted its position in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock worth $283,000 after buying an additional 5,229 shares during the last quarter. Y Intercept Hong Kong Ltd lifted its position in shares of MoonLake Immunotherapeutics by 55.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 20,325 shares of the company’s stock worth $1,025,000 after buying an additional 7,247 shares during the last quarter. Finally, State Street Corp lifted its position in shares of MoonLake Immunotherapeutics by 96.2% during the 3rd quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after buying an additional 42,980 shares during the last quarter. 93.85% of the stock is owned by institutional investors and hedge funds.

MoonLake Immunotherapeutics Trading Down 0.9 %

MoonLake Immunotherapeutics stock opened at $43.21 on Tuesday. The company has a market capitalization of $2.76 billion, a PE ratio of -33.50 and a beta of 1.28. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $64.00. The stock has a 50-day moving average price of $48.52 and a two-hundred day moving average price of $49.10.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th. The Goldman Sachs Group upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $62.00 to $82.00 in a research report on Friday, January 17th. Finally, Wedbush restated an “outperform” rating and set a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $85.50.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.